Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jeffrey Kirshner MD, FACP, FASCO
Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board
Jean-Yves Douillard MD, PhD
Jean-Yves Douillard MD, PhD Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · September 28, 2023

Cancer Vaccine OSE2101 vs Chemotherapy in HLA-A2–Positive Patients With Advanced NSCLC Resistant to Immunotherapy

Annals of Oncology

 

 Save  Recommend
 Share

Additional Info

Annals of Oncology
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
Ann. Oncol 2023 Aug 01;[EPub Ahead of Print], B Besse, E Felip, RG Campelo, M Cobo, C Mascaux, A Madroszyk, F Cappuzzo, W Hilgers, G Romano, F Denis, S Viteri, D Debieuvre, D Galetta, E Baldini, M Razaq, G Robinet, M Maio, A Delmonte, B Roch, P Masson, W Schuette, A Zer, J Remon, D Costantini, B Vasseur, R Dziadziuszko, G Giaccone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated